ReSynapse Therapeutics
General Data
Reg Number
517161493
Sector
Biomed
Established
2025
No. of Employees
5
Stage
Seed
Additional Funding
1
Description
ReSynapse Therapeutics develops novel single-molecule multi-target drugs for selective serotonin modulation to treat PTSD. Our differentiation edge is a mechanism-based receptor combination to identify single molecules that hit the identified combination.
Technology
Big data, medtech.
Targeted Customers
Physicians.
Winning details
Route name
Winning year
Increasing participation of Israeli industrial corporations in the European Horizon program
Increasing participation of Israeli industrial corporations in the European Horizon program
2025